Morphological effects of vitamin D and its analogs on bone.
Recent studies employing analogs of vitamin D in the treatment of clinical and experimental renal osteodystrophy indicate remarkable healing of morphological and biochemical skeletal lesions. After short periods of therapy, 25-hydroxycholecalciferol or 1,25-dihydroxycholecalciferol normalizes most of the histological abnormalities of the human uremic skeleton and significantly suppresses elevated levels of circulating immunoreactive parathyroid hormone. 25-Hydroxycholecalciferol appears to stimulate individual osteoblastic activity but does not increase the number of bone forming cells. Accumulated evidence suggests a direct effect of vitamin D and its metabolites on uremic bone.
D000818:Animals; D001846:Bone Development / Q000187:drug effects; D001853:Bone Marrow / Q000473:pathology; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy*; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D010006:Osteoblasts / Q000187:drug effects; D014511:Uremia / Q000188:drug therapy / Q000473:pathology; D014807:Vitamin D / Q000378:metabolism / Q000627:therapeutic use*
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D014807:Vitamin D